Literature DB >> 20237087

Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies.

Simrat Dhillon1, Jeroen Witteveldt, Derek Gatherer, Ania M Owsianka, Mirjam B Zeisel, Muhammad N Zahid, Malgorzata Rychłowska, Steven K H Foung, Thomas F Baumert, Allan G N Angus, Arvind H Patel.   

Abstract

Cell culture-adaptive mutations within the hepatitis C virus (HCV) E2 glycoprotein have been widely reported. We identify here a single mutation (N415D) in E2 that arose during long-term passaging of HCV strain JFH1-infected cells. This mutation was located within E2 residues 412 to 423, a highly conserved region that is recognized by several broadly neutralizing antibodies, including the mouse monoclonal antibody (MAb) AP33. Introduction of N415D into the wild-type (WT) JFH1 genome increased the affinity of E2 to the CD81 receptor and made the virus less sensitive to neutralization by an antiserum to another essential entry factor, SR-BI. Unlike JFH1(WT), the JFH1(N415D) was not neutralized by AP33. In contrast, it was highly sensitive to neutralization by patient-derived antibodies, suggesting an increased availability of other neutralizing epitopes on the virus particle. We included in this analysis viruses carrying four other single mutations located within this conserved E2 region: T416A, N417S, and I422L were cell culture-adaptive mutations reported previously, while G418D was generated here by growing JFH1(WT) under MAb AP33 selective pressure. MAb AP33 neutralized JFH1(T416A) and JFH1(I422L) more efficiently than the WT virus, while neutralization of JFH1(N417S) and JFH1(G418D) was abrogated. The properties of all of these viruses in terms of receptor reactivity and neutralization by human antibodies were similar to JFH1(N415D), highlighting the importance of the E2 412-423 region in virus entry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237087      PMCID: PMC2876616          DOI: 10.1128/JVI.02153-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Authors:  Mario Perotti; Nicasio Mancini; Roberta A Diotti; Alexander W Tarr; Jonathan K Ball; Ania Owsianka; R Adair; Arvind H Patel; Massimo Clementi; Roberto Burioni
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 2.  CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system.

Authors:  S Levy; S C Todd; H T Maecker
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

3.  An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.

Authors:  Birke Bartosch; Géraldine Verney; Marlène Dreux; Peggy Donot; Yoann Morice; François Penin; Jean-Michel Pawlotsky; Dimitri Lavillette; Francois-Loïc Cosset
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.

Authors:  Dimitri Lavillette; Alexander W Tarr; Cécile Voisset; Peggy Donot; Birke Bartosch; Christine Bain; Arvind H Patel; Jean Dubuisson; Jonathan K Ball; François-Loïc Cosset
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

5.  Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Authors:  M Flint; C Maidens; L D Loomis-Price; C Shotton; J Dubuisson; P Monk; A Higginbottom; S Levy; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.

Authors:  Cécile Voisset; Nathalie Callens; Emmanuelle Blanchard; Anne Op De Beeck; Jean Dubuisson; Ngoc Vu-Dac
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

7.  Binding of hepatitis C virus to CD81.

Authors:  P Pileri; Y Uematsu; S Campagnoli; G Galli; F Falugi; R Petracca; A J Weiner; M Houghton; D Rosa; G Grandi; S Abrignani
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

8.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.

Authors:  H Nakabayashi; K Taketa; K Miyano; T Yamane; J Sato
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

9.  Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus.

Authors:  Teresa J Broering; Kerry A Garrity; Naomi K Boatright; Susan E Sloan; Frantisek Sandor; William D Thomas; Gyongyi Szabo; Robert W Finberg; Donna M Ambrosino; Gregory J Babcock
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

10.  MAFFT version 5: improvement in accuracy of multiple sequence alignment.

Authors:  Kazutaka Katoh; Kei-ichi Kuma; Hiroyuki Toh; Takashi Miyata
Journal:  Nucleic Acids Res       Date:  2005-01-20       Impact factor: 16.971

View more
  39 in total

1.  Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

Authors:  Haihong Zhu; Flossie Wong-Staal; Haekyung Lee; Andrew Syder; Jeffrey McKelvy; Robert T Schooley; David L Wyles
Journal:  J Infect Dis       Date:  2012-02-15       Impact factor: 5.226

2.  A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.

Authors:  Adam Zuiani; Kevin Chen; Megan C Schwarz; James P White; Vincent C Luca; Daved H Fremont; David Wang; Matthew J Evans; Michael S Diamond
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

3.  Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Authors:  Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Yong Wang; Patrick Lau; Thomas Krey; Felix A Rey; Steven K H Foung
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.

Authors:  Leopold Kong; Erick Giang; Justin B Robbins; Robyn L Stanfield; Dennis R Burton; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

6.  Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

Authors:  Chaturaka Rodrigo; Melanie R Walker; Preston Leung; Auda A Eltahla; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Sunita Dwivedi; Julie Bruneau; Meghan D Morris; Andrea L Cox; William Osburn; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  Infect Genet Evol       Date:  2017-01-05       Impact factor: 3.342

7.  Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33.

Authors:  Leopold Kong; Erick Giang; Travis Nieusma; Justin B Robbins; Marc C Deller; Robyn L Stanfield; Ian A Wilson; Mansun Law
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

8.  Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.

Authors:  Christian K Mathiesen; Tanja B Jensen; Jannick Prentoe; Henrik Krarup; Alfredo Nicosia; Mansun Law; Jens Bukh; Judith M Gottwein
Journal:  Virology       Date:  2014-05-24       Impact factor: 3.616

9.  Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.

Authors:  Jane A Potter; Ania M Owsianka; Nathan Jeffery; David J Matthews; Zhen-Yong Keck; Patrick Lau; Steven K H Foung; Garry L Taylor; Arvind H Patel
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

10.  Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.

Authors:  Mark S Sulkowski; Minhee Kang; Roy Matining; David Wyles; Victoria A Johnson; Gene D Morse; Valerianna Amorosa; Debika Bhattacharya; Kristine Coughlin; Flossie Wong-Staal; Marshall J Glesby
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.